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The fluorescence properties of the new potent antitumoral methyl 3-amino-6-(benzo[d]thiazol-
2-ylamino)thieno[3,2-b]pyridine-2-carboxylate in solution and when encapsulated in several 
different nanoliposome formulations were investigated. The compound exhibits very 
reasonable fluorescence quantum yields and a solvent sensitive emission in several polar and 
non-polar media, despite not being fluorescent in protic solvents.  
Fluorescence anisotropy measurements of the compound incorporated in liposomes revealed 
that this thienopyridine derivative can be carried in the hydrophobic region of the lipid 
membrane. Liposome formulations including this antitumor compound are nanometric in size, 
with a diameter lower than 130 nm and generally low polydispersity, being promising for 
future drug delivery developments. 
The interaction of the compound with bovine serum albumin (BSA) and the multidrug 
resistance protein MDR1 was monitored by FRET, the compound acting as energy acceptor.  It 
was observed a lower interaction with MDR1 protein than with the native form of BSA, which 
is an important result regarding applications of this antitumoral drug. 
 
 
Introduction  
Thienopyridine derivatives have attracted much attention as 
they exhibit important biological activity, namely as 
antitumoral agents,1-5 nonreceptor Src kinase inhibitors,6 
receptor tyrosine kinase7 and vascular endothelial growth factor 
(VEGFR-2) inhibitors,8-9 the latter related to angiogenesis and 
metastasis. 
The methyl 3-amino-6-(benzo[d]thiazol-2-ylamino)-
thieno[3,2-b]pyridine-2-carboxylate (1) (Figure 1) was 
previously synthetized by us by palladium-catalysed C-N 
Buchwald-Hartwig coupling.2 Compound 1 showed to be the 
most potent antitumor compound among a series of synthesized 
methyl 3-amino-6-[(hetero)arylamino]thieno[3,2-b]pyridine-2-
carboxylates, presenting very low growth inhibitory 
concentration values (GI50) between 3.5 and 6.9 µM, when 
tested in vitro (with a 24h incubation time and using DMSO as 
solvent) against several human tumour cell lines, MCF-7 
(breast adenocarcinoma), A375-C5 (melanoma) and NCI-H460 
(non-small cell lung cancer).2  
Due to this potent antitumor activity of compound 1, which 
is the most active of a series of analogues,2 its behaviour in 
liposomes and when interacting with both plasma and 
membrane proteins is of particular interest, considering future 
developments using this thienopyridine derivative as an 
antitumoral drug. 
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Compound 1 
Fig. 1 Structure of the methyl 3-amino-6-(benzo[d]thiazol-2-
ylamino)thieno[3,2-b]pyridine-2-carboxylate (1). 
The multidrug resistance is one of the major gaps of many 
forms of chemotherapy, which can be associated with an 
overexpression of drug pumps. These pumps are usually 
membrane proteins and the study of drug interaction with such 
proteins may be useful for reversing drug resistance in 
cancer.10 Multidrug transport proteins can actively remove 
toxic compounds and are of fundamental importance in the 
resistance to both antibiotics and anticancer drugs.11,12  
The interaction with human and bovine serum albumins 
(HSA and BSA, respectively) has also been extensively studied 
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for several drugs, among others for efonidipine (an 
antihypertensive and antianginal agent),13 quercetin (flavonoid 
antioxidant agent),14 ceftriaxone (antibiotic),15 alprazolam 
(psychotropic drug)16 and anastrozole (anticancer drug).17 In 
particular, BSA is used as a model for HSA as, upon sequence 
alignment, they share about 76% of the amino acid sequence 
identity. Serum albumin, while being responsible for the 
osmotic pressure of the blood (among other key roles), acts as 
vehicle for long chain fatty acids, vitamins, amino acids, 
hormones, some metal ions (Zn2+, Cu2+) and drugs like 
penicillins and benzodiazepines.18-21 In this work, we 
investigate whether BSA is able to bind and carry compound 1 
in the blood stream. 
 Nanoliposomes are promising systems in drug delivery and 
their stability and efficiency is strongly related with their 
composition.22,23 Considering the very low solubility of  
compound 1 in aqueous media, the use of liposomes as 
transport vehicles is of special importance. Is has been reported 
that the presence of cholesterol may increase the stability of the 
lipid vesicles by preventing crystallization of the phospholipid 
acyl chains and providing steric hindrance to their movement, 
while also acting as modulator of the bilayer fluidity. Recently, 
the phospholipid DMPG has been widely employed in 
liposome formulations, as it provides the formation of pores 
across the lipid membrane24 which has a promising biological 
relevance in controlled release from nanocompartments.25 
Advances in liposome research also found that PEG allows 
longer circulatory life of the drug delivery system, while being 
inert in the body.26 
In this work, compound 1 was incorporated in several 
nanoliposome formulations, and its behaviour was studied by 
fluorescence. The interaction of this antitumoral drug with the 
plasma protein BSA and the multidrug resistance protein 
MDR1 was evaluated by FRET (Förster Resonance Energy 
Transfer). 
Experimental  
Materials and Methods 
All the solutions were prepared using spectroscopic grade 
solvents and ultrapure water (Milli-Q grade). The proteins 
Bovine Serum Albumin (lyophilized powder) and human 
MDR1 (membrane preparation expressed in Sf9 cells) were 
obtained from Sigma-Aldrich. 
 Buffers with pH values of 2, 5 and 7 were prepared 
according to a standard procedure,27 using a mixed solution of 
0.2 M boric acid and 0.05 M citric acid and a 0.1 M solution of 
sodium phosphate. 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
diacyl-sn-glycero-3-phosphocholine from egg yolk (Egg-PC), 
1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodi-
um salt) (DPPG), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-
(1-glycerol)] (sodium salt) (DMPG) and cholesterol (Ch) were 
obtained from Sigma-Aldrich. 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(ammonium salt) (DSPE-PEG) was obtained from Avanti Polar 
Lipids, while dioctadecyldimethylammonium bromide 
(DODAB) was purchased from Tokyo Kasei. Lipid structures 
are shown in Figure 2.  
For Egg-PC membranes preparation, defined volumes of 
stock solutions of lipid and compound in ethanol were injected 
together, under vigorous stirring, to an aqueous buffer solution 
(10 mM Tris-HCl buffer, pH=7.4), at room temperature 
(ethanolic injection method28,29). A similar procedure was 
adopted for the other lipid membranes and lipid formulations, 
but the injection of the required amounts of stock solutions of 
lipid and compound in ethanol were done at 60 ˚C, well above 
the lipids melting transition temperature (41 ºC for DPPC,30 40 
ºC for DPPG,31 23 ºC for DMPG32 and 45 ºC for DODAB33), 
followed by six extrusion cycles (using a LIPEXTM extruder) 
through 100 nm polycarbonate membranes. Extrusion 
technique was used to diminish the mean diameter and 
polydispersity of the liposomes, making them suitable for 
nanoscale delivery. Between the extrusion cycles, the solutions 
were allowed to equilibrate for 1 hour. The final total lipid 
concentration was 1 mM, with a compound/lipid molar ratio of 
1:500. Fluorescence measurements in liposomes were 
performed using samples prepared with this same protocol. 
 
 
Fig. 2 Structures of the lipids used in nanoliposomes 
formulations. 
DLS measurements  
Liposomes mean diameter and size distribution (polydispersity 
index) were measured using a Dynamic Light Scattering (DLS) 
equipment (NANO ZS Malvern Zetasizer), at 25 ºC, using a 
He-Ne laser of 633 nm and a detector angle of 173º. Five 
independent measurements were performed for each sample. 
Malvern Dispersion Technology Software (DTS) was used 
with multiple narrow mode (high resolution) data processing, 
and mean size (nm) and error values were considered. 
Spectroscopic measurements  
General methods. Absorption spectra were recorded in a Shimadzu 
UV-3101 PC UV-Vis-NIR spectrophotometer. Fluorescence 
measurements were performed using a Fluorolog 3 
spectrofluorimeter, equipped with double monochromators in both 
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excitation and emission, Glan-Thompson polarizers and a 
temperature controlled cuvette holder.  
For fluorescence quantum yield determination, the solutions were 
previously bubbled for 30 minutes with ultrapure nitrogen. 
Fluorescence spectra were corrected for the instrumental response of 
the system.  
The fluorescence quantum yields (S) were determined using 
the standard method (equation 1).34,35 The IUPAC recommendations 
for this method were followed.36 Quinine sulfate in 0.05 M sulfuric 
acid was used as reference, r = 0.546 at 25 ºC.
37 
 
     r2rrs2ssrs  nFAnFA                                                     (1)  
where A is the absorbance at the excitation wavelength, F the 
integrated emission area and n is the refraction index of the solvents. 
Subscripts refer to the reference (r) or sample (s) compound. The 
absorbance value at excitation wavelength was always less than 0.1, 
in order to avoid inner filter effects.  
The Lippert-Mataga equation (equation 2), where the energy 
difference between absorption and emission maxima is related to the 
polarizability of the solvent,38,39 was used to describe the 
solvatochromic shifts of compound 1, 
            (2) 
where  is the wavenumber of maximum absorption,  is the 
wavenumber of maximum emission,  = e – g is the difference 
in the dipole moment of solute molecule between excited (e) and 
ground (g) states, R is the cavity radius, and f is the polarizability 
of the solvent, given by (equation 3): 
  ,                                   (3)  
where  is the static dielectric constant and n the refractive index of 
the solvent.  
The steady-state fluorescence anisotropy, r, is calculated by 
                        (4) 
where IVV and IVH are the intensities of the emission spectra 
obtained with vertical and horizontal polarization, respectively (for 
vertically polarized excitation light), and  is the 
instrument correction factor, where IHV and IHH are the emission 
intensities obtained with vertical and horizontal polarization (for 
horizontally polarized excitation light). 
FRET measurements. The interaction of compound 1 with proteins 
was evaluated by Förster Resonance Energy Transfer (FRET). For 
these experiments, the compound was dissolved in ethanol and 
injected in each protein solution. 
FRET efficiency, ΦRET, defined as the proportion of donor 
molecules that have transferred their excess energy to acceptor 
molecules, was calculated through donor emission quenching, by 
taking the ratio of the donor integrated fluorescence intensities in the 
presence of acceptor (FDA) and in the absence of acceptor (FD) 
(equation 5).40 
ΦRET = 1 - 
FDA
FD
                                                 (5) 
The distance between donor and acceptor molecules can be 
determined through the FRET efficiency (equation 6),  
𝑟AD = 𝑅0. [
1−ΦRET
ΦRET
]
1
6⁄
                                  (6) 
where R0 is the Förster radius (critical distance), that can be obtained 
by the spectral overlap, J(λ), between the donor emission and the 
acceptor absorption, according to equations (7) and (8) (with R0 in 
Å,  in nm, A() in M
-1 cm-1),40 
𝑅0 = 0.2108[𝑘
2D
0𝑛−4𝐽(𝜆)]
1
6⁄                             (7) 
    
𝐽(𝜆) =  ∫ 𝐼𝐷(𝜆
∞
0
)𝜀𝐴(𝜆)𝜆
4𝑑𝜆                            (8) 
where 𝑘2 = 2 3⁄
 is the orientational factor assuming random 
orientation of the dyes, Φ𝐷
0  is the fluorescence quantum yield of the 
donor in the absence of energy transfer, n is the refraction index of 
the medium, ID(λ) is the fluorescence spectrum of the donor 
normalized so that ∫ 𝐼𝐷
∞
0
(𝜆)𝑑𝜆 = 1, and A(λ) is the molar 
absorption coefficient of the acceptor. 
Results and Discussion 
Photophysical properties in solution 
The promising antitumoral properties of the thienopyridine 1 (Figure 
1) inspired us to study the photophysical behaviour of this 
fluorescent compound in solution, as it is important for the 
understanding of compound interaction with proteins and liposomes. 
Therefore, the absorption and fluorescence properties of the 
thienopyridine derivative 1 were studied in several solvents of 
different polarity. The maximum absorption (abs) and emission 
wavelengths (em), molar absorption coefficients and fluorescence 
quantum yields of this compound are shown in Table 1. The 
normalized fluorescence spectra are shown in Figure 3 (examples of 
absorption spectra are displayed as insets). 
 
Fig. 3 Normalized fluorescence spectra (exc=360 nm) of 310
-6 M 
solutions of compound 1 in several solvents. Inset: Absorption 
spectra of 210-5 M solutions of compound in dichloromethane and 
cyclohexane, as examples. 
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Compound 1 presents moderate absorption coefficient values (ε 
≥ 3103 M–1 cm–1) in all solvents (at the lowest energy absorption 
maximum) and also exhibits reasonable ﬂuorescence quantum yields 
(Table 1). This behaviour in absorption and emission is common to 
other thienopyridine derivatives previously studied,41-43 and was 
attributed to a state mixing between a ππ* transition (aromatic 
ring system) and a nπ* transition (carbonyl group).44 
Compound 1 is not fluorescent in protic solvents, pointing to 
hydrogen bond formation with this kind of solvents, or by 
protonation of the N atom of the pyridine ring, as already reported 
by us for methoxylated di(hetero)arylethers in the thieno[3,2-
b]pyridine series41 and for 1,3-diarylureas linked to methyl 3-
aminothieno[3,2-b]pyridine-2-carboxylate moiety.42 Also a common 
feature is the significant red shifts observed for emission in polar 
solvents (32 nm between cyclohexane and dimethylsulfoxide) 
(Figure 3), usually attributed to an intramolecular charge transfer 
(ICT) mechanism or to specific solvent effects,38 indicating a major 
role for solvent relaxation after photoexcitation. 
The solvatochromic shifts were plotted using the Lippert-
Mataga equation (equation 2, Figure 4). This plot is reasonably 
linear and the high slope value allows concluding that compound 1 
has a pronounced ICT character in the excited state.  
With Gaussian 09 software46 and use of a 6-311+G(dp) basis set 
at the TD-SCF DFT (MPW1PW91) level of theory47 in gas phase, 
the optimized geometries of the ground and the first excited singlet 
states were obtained (Figure 5), showing that the ring systems are 
completely planar. The blue arrows indicate the direction of the 
calculated dipole moments, pointing to a change in direction of the 
excited state dipole moment relative to the ground state. Absolute 
values of dipole moments, g=3.53 D and e=4.46 D, and a cavity 
radius of R=5.53 Å were estimated by Gaussian calculations. Using 
the vectors coordinates, the magnitude of dipole moment difference, 
|μ⃗ e − μ⃗ g|= 6.47 D, is lower than the predicted from the Lippert-
Mataga solvatochromic plot (Figure 4), |μ⃗ e − μ⃗ g|= 8.96 D, as the 
latter does not include the change in the vector direction. 
Table 1. Maximum absorption (abs) and emission (em) wavelengths, molar absorption coefficients (ε) and fluorescence quantum yields 
(F) for the thieno[3,2-b]pyridine derivative 1 in several solvents. 
Solvent λabs (nm) (ε /10
4 M-1 cm-1) λem (nm) F 
a 
Cyclohexane 374 (0.39); 298 (2.55); 235 (1.57) 460 0.43 
Dioxane 372 (0.48); 299 (2.34); 237 (1.71) 472 0.40 
Chloroformb 368 (0.51); 299 (2.74) 464 0.14 
Ethyl acetateb 369 (0.52); 322 (0.88); 298 (2.66) 470 0.17 
Dichloromethane 367 (0.51); 323 (0.89); 298 (2.71); 235 (1.79) 469 0.22 
Dimethylsulfoxideb 369 (0.91); 341 (1.23) 492 0.32 
N,N-Dimethylformamideb 367 (1.09); 342 (1.53); 290 (3.34) 484 0.23 
Acetonitrile 362 (0.60); 324 (0.91); 296 (2.47); 235 (1.75) 478 0.14 
Ethanol 365 (0.63); 325 (0.93); 299 (2.24) --- --- 
Methanol 365 (0.61); 324 (0.94); 298 (2.29) --- --- 
Water 366 (0.31); 324 (0.63); 299 (1.28) --- --- 
a Relative to quinine sulfate in 0.05M sulfuric acid (r =0.546).
37  Error about 10%. 
b Solvents cut-off: chloroform: 250 nm; ethyl acetate: 265 nm; dimethylsulfoxide: 270 nm; N,N-dimethylformamide: 275 nm. 
 
 
Fig. 4 Lippert-Mataga plot for compound 1. Solvents: 1 – 
cyclohexane; 2 – dioxane; 3 – chloroform; 4 – ethyl acetate; 5 – 
dichloromethane; 6 – dimethylsulfoxide; 7 – N,N-dimethylforma-
mide; 8 – acetonitrile (values of  and n were obtained from ref. 45). 
 
Fig. 5 Optimized geometries for compound 1 calculated by 
Gaussian 09 software (grey: C atoms; white: H atoms; red: O atoms; 
blue: N atoms; yellow: S atoms). Left: ground state; Right: lowest 
excited singlet state. The arrows indicate the direction of the dipole 
moment. 
The representation of the electronic density difference between 
the lowest excited state and ground state is displayed in Figure 6A, 
as well as the corresponding centroids of either the electronic 
depletion (C+) or increment (C-)
48 that occurs upon electronic 
excitation, using the lowest excited state optimized geometry 
(relaxed S1 state) (Figure 6B).  
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Fig. 6 A. Electronic density difference (optimized geometry for the 
lowest excited singlet state) at an iso level of 0.001; green regions: 
loss of electronic density; red regions: enrichment of electronic 
density. B. Centroids of electronic charge density depletion (C+, 
green) or increment (C-, red) at the same iso level. 
 
The electron density variations occur mostly on the thieno[3,2-
b]pyridine moiety, which is a common behavior with other 
thieno[3,2-b]pyridine derivatives already synthesized by some of us, 
namely 1,3-diaylurea derivatives42 and 6-(hetero)arylthieno[3,2-
b]pyridines.43 The charge transfer character of the excited state is 
confirmed by the electron density transfer from the amino group 
linked to the thiophene ring of thienopyridine moiety and its sulfur 
atom to the pyridine moiety (Figure 6A). The distance of 1.82 Å 
between the barycenters of charge density also supports the charge 
transfer character. The calculations of densities of charge increase 
and depletion (figure 6B) were performed with the help of the 
Multiwfn software package.49  
The significant sensitivity of the fluorescence emission of 
compound 1 to its environment can be useful when probing the 
location/behavior of this antitumoral thienopyridine derivative in 
liposomes of several compositions. 
Incorporation of compound 1 in nanoliposomes 
The thienopyridine derivative 1 was encapsulated in liposomes of 
different compositions, either composed of neat lipids or lipid 
formulations based on previous work, including cholesterol and 
PEG.30,43,50 The influence of the surface charge was investigated, 
using zwitterionic phospholipids (the phosphatidylcholines Egg-PC 
and DPPC), anionic lipids (DPPG, DMPG) and a cationic synthetic 
amphiphile (DODAB).  
DLS measurements. In order to obtain information about the more 
promising liposome formulations for the incorporation of compound 
1, the mean size and size distribution (polydispersity, PdI) of the 
nanoliposome formulations containing this compound were 
determined by Dynamic Light Scattering (DLS) (Table 2). This is 
especially important considering the emerging nanoscale delivery 
systems using liposomes for the delivery of drugs in disease 
treatment.22 
DLS measurements indicate that all the nanoliposomes tested 
with the incorporated compound 1 have low polydispersity (PdI < 
0.4) and with hydrodynamic diameters between 60 and 125 nm. As 
previously reported for other thienopyridine derivatives,41,43 the 
formulations based in Egg-PC have generally the smallest sizes and 
low polydispersity. It can also be observed that the inclusion of 
DMPG causes a diminution in size of liposomes containing 50% 
DMPG or above, with diameters lower than 100 nm (Table 2). 
PEGylation induces a small increase in particle diameter with a 
decrease in polydispersity (Table 2). On the other hand, the more 
polydisperse formulations are the ones rich in DPPC (DPPC:Ch 7:3 
and DPPC:DMPG 2:1). 
 
Table 2. Hydrodynamic diameter and polydispersity of several 
liposome formulations containing the thienopyridine derivative 1, at 
25 ºC.  
Formulation 
Hydrodynamic 
diameter (nm) 
(mean  SD) 
Polydispersity 
(mean ± SD) 
Egg-PC:Ch (7:3) 84 ± 2 0.233 ± 0.004 
Egg-PC:Ch:DMPG (7:3:1) 63.7 ± 0.4 0.284 ± 0.003 
DPPC:DMPG (1:1) 99 ± 3 0.33 ± 0.04 
DPPC:DMPG (2:1) 124 ± 1 0.38 ±0.07 
DPPC:DMPG (1:2) 91 ± 1 0.23 ± 0.01 
DPPC:Ch (7:3) 110 ± 3 0.38 ± 0.08 
DPPC:Ch:DSPE-PEG (7:3:1) 117 ± 1 0.27 ± 0.01 
Standard deviations (SD) were calculated from the mean of the data of a 
series of five experiments conducted using the same parameters. 
Fluorescence measurements. Fluorescence emission spectra 
of the thienopyridine derivative 1 in liposomes were measured 
in both gel (below the melting temperature, Tm) and liquid-
crystalline (above Tm) phases of each lipid. The lipids DPPC, 
DPPG and DODAB are in the gel phase at room temperature, 
while the egg phosphatidylcholine is in the fluid phase (Tm is 
very low for this phosphatidylcholines mixture51). The spectra 
are shown in Figure 7 (maximum emission wavelengths are 
presented in Table 3).  
Fig. 7 Normalized fluorescence spectra of compound 1 (3×10-6 M) 
in liposomes of several compositions, at room temperature (λexc = 
360 nm). 
Relevant information about the location/behavior of this 
antitumoral compound in liposomes can be obtained through 
fluorescence anisotropy (r) measurements, as the r value increases 
with the rotational correlation time of the fluorescent molecule (and, 
thus, with the viscosity of the environment, equation 9)40 

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                            (9)  
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where r0 is the fundamental anisotropy,  is the excited-state lifetime 
and c is the rotational correlation time. 
The fluorescence (steady-state) anisotropies of this 
thienopyridine derivative in the several liposomes are shown in 
Table 3. For comparison, the fluorescence anisotropy in glycerol (a 
very viscous solvent, =993.4 cP at 25 ºC 45) at room temperature 
was also determined (r = 0.327). An increase of the steady-state 
anisotropy is expected from a diminution of the excited-state 
lifetime (equation 9). Upon temperature increase, the excited-state 
lifetime is predicted to decrease, due to the increment of the non-
radiative deactivation pathways, especially the rate constant for 
internal conversion S1→S0. As the anisotropy value decreases 
strongly at higher temperature (Table 3), this behavior can be 
attributed to a decrease of the rotational correlation time of the 
fluorophore. This originates from the decrease of membrane 
microviscosity upon changing from the gel to the liquid-crystalline 
phase of the lipids DPPC (Tm=41 ºC),
30 DPPG (Tm=40 ºC)
31 and 
DODAB (Tm=45 ºC).
33 
 
Table 3. Steady-state fluorescence anisotropy (r) values and 
maximum emission wavelengths (em) for compound 1 in several 
liposome formulations, at 25 ºC and 55 ºC. 
Lipid formulation Temp. λem (nm) r 
Egg-PC (100%) 25 ºC 459 0.176 
DPPC (100%) 
25 ºC 460 0.256 
55 ºC 458 0.130 
DPPG (100%) 
25 ºC 479 0.186 
55 ºC 477 0.129 
DODAB (100%) 
25 ºC 480 0.153 
55 ºC 479 0.071 
Egg-PC:Ch (7:3) 25 ºC 458 0.137 
Egg-PC:Ch:DMPG (7:3:1) 25 ºC 466 0.122 
DPPC:Ch (7:3) 
25 ºC 461 0.129 
55 ºC 459 0.102 
DPPC:DMPG (1:1) 
25 ºC 479 0.224 
55 ºC 477 0.084 
DPPC:DMPG (2:1) 
25 ºC 478 0.225 
55 ºC 476 0.093 
DPPC:DMPG (1:2) 
25 ºC 479 0.215 
55 ºC 478 0.074 
DPPC:Ch:DSPE-PEG 
(7:3:1) 
25 ºC 476 0.124 
55 ºC 474 0.104 
To analyse and compare the steady-state fluorescence anisotropy 
values at room temperature (Table 3), the Strickler-Berg equation,52 
relating the radiative lifetime with the absorption intensity (equation 
10) could be used  
 
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          (10) 
where r is the radiative lifetime, n is the index of refraction,  is the 
molar absorption coefficient, and  FF  is the fluorescence 
intensity per unit wavenumber. This quantity is related to the 
fluorescence quantum yield,40 through  
  F
0
FF d  F
           (11) 
 
Fluorescence quantum yields of compound 1 in neat liposomes 
were determined by the standard method34,35 (equation 1) as 
F=0.11 in DPPC, F=0.08 in DPPG, F=0.07 in DODAB, and 
F=0.11 in Egg-PC. These values are roughly similar and, as the 
absorption spectra in the several liposomes are also analogous, the 
Stickler-Berg relation (equation 10) predicts an approximately 
constant value for the radiative lifetime in all the lipid vesicles.  
The fluorescence quantum yield and the excited-state lifetime 
are related by equation 12,   
F = kr                           (12) 
where kr=1/r is the rate constant for radiative deactivation with 
fluorescence emission.40 Taking this into account, we can conclude 
that the compound excited-state lifetime is approximately constant 
for the studied liposomes at 25 ºC. Therefore, variations in 
fluorescence anisotropy at room temperature can be directly related 
to changes in the rotational correlation time of the fluorescent 
compound and, thus, to changes in the microviscosity of its 
surrounding medium.  
The differences in anisotropy values between the compound 
incorporated in the several lipid aggregates and in glycerol at room 
temperature can also be attributed to the distinct environment 
viscosities,43 as glycerol is much more viscous than lipid 
membranes, which viscosity values are around 100-200 cP.53,54  
In neat DPPG (anionic) and DODAB (cationic) aggregates, as 
well as in DMPG-containing formulations, the maximum emission 
wavelengths point to a more hydrated environment than in 
zwitterionic Egg-PC or DPPC aggregates (Table 3). Anisotropy 
values are also lower for neat DPPG and DODAB than for neat 
DPPC, indicating that an increased hydration also corresponds to an 
increased membrane fluidity where the compound molecules are 
located. The influence of the lipid charge seems to be negligible in 
compound behaviour, pointing to a main location in the beginning 
of the inner membrane, due to its hydrophobic character.  
The influence of DMPG in the liposomes properties can be 
attributed to the ability of this phospholipid to create perforations in 
the lipid bilayers,24,25 inducing also a more hydrated environment for 
the thienopyridine derivative in DMPG-rich systems. The effect of 
cholesterol (Ch) seems to be a rise in fluidity of the lipid 
membranes, as previously reported,42,43 which can be inferred from 
the significant decrease in anisotropy at room temperature in Ch-
containing systems. The presence of PEG does not influence 
compound anisotropy, which can be explained by a deep location of 
the fluorophore in the lipid membranes, while PEG usually covers 
the lipid aggregates. 
 
Interaction with proteins 
Considering the promising antitumoral properties of compound 1, its 
interaction with proteins was also investigated. A plasma protein, 
Bovine Serum Albumin (BSA), and a membrane protein (human 
multidrug resistance MDR1) were employed in this study. The 
interaction was evaluated by FRET (Förster Resonance Energy 
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Transfer) from the protein amino acids tyrosine and tryptophan to 
the fluorescent compound 1.  
 It is known that BSA protein has pH-dependent conformations, 
undergoing a transition from the extended form to the native form 
when pH increases from 2.7 to 4.3.55 Therefore, these studies were 
performed at three different pH values (2, 5 and 7), as 
conformational changes can markedly influence the compound 
affinity to BSA. Figure 8 shows the spectral overlap between the 
fluorescence emission of proteins MDR1 and BSA, the latter in both 
the native (pH=7) and extended (pH=2) forms, and the absorption of 
compound 1, evidencing the possibility of FRET between each 
protein (donor) and compound 1 (acceptor). 
 
Fig. 8 Spectral overlap between the fluorescence emission of both 
MDR1 and BSA (at pH=2 and pH=7) and the absorption of 
compound 1. 
 
 
FRET measurements were performed at several 
protein/compound molar ratios, keeping constant compound 
concentration. Exciting in the region where proteins absorb, through 
the aromatic amino acids tyrosine and tryptophan (exc=280 nm), it 
is possible to observe the fluorescence emission of compound 
(max=450 nm) (Figures 9 and 10). At exc=280 nm, compound 1 is 
also directly excited (Figure 8) but, as it is not fluorescent in 
aqueous media, the observation of compound fluorescence can only 
be due to the interaction between this thienopyridine and the 
proteins, either due to FRET from BSA/MDR1, or due to the 
compound location in hydrophobic protein domains. 
For BSA, [protein]/[compound] ratios of 0.5:1, 1:1, 2:1 and 4:1 
were investigated, corresponding to [amino acid]/[compound] ratios 
of 292:1, 583:1, 1166:1 and 2332:1, respectively, as BSA molecule 
has 583 amino acids (from which 20 tyrosines and 2 tryptophans per 
chain).56 
Figure 9 shows the fluorescence emission of compound 1 in the 
presence of BSA at different pH values, for [BSA]/[1]=1. The ratio 
of emission intensities between the compound and protein is 
displayed at inset, as function of protein concentration for the 
several pH values. Compound emission is clearly higher at pH=7 
(BSA in native form), especially at smaller protein concentrations. 
However, at pH=2, the fluorescence emission of the compound is 
not detected at any protein/compound ratio.  
 
Fig. 9 Fluorescence spectra of BSA/compound solutions (exc = 280 
nm) at pH=2; 5; 7 for [BSA]/[compound]=1:1. Inset: Ratio of 
fluorescence intensities between compound and BSA as function of 
BSA concentration. 
 
Figure 10 displays the excitation spectra, with the emission 
collected at compound fluorescence band (em=450 nm) for 
[BSA]/[compound]=1, as an example. Excitation spectrum at pH=7 
resembles the absorption spectrum of compound 1, with additional 
bands of the amino acids that transfer their excitation energy to 
compound 1. The excitation spectrum at pH=2 (Figure 10), showing 
a very low intensity, resembles the absorption spectrum of the 
compound with much less features of the amino acids absorption. 
This clearly indicates a very low energy transfer efficiency at pH=2. 
The interaction of this thienopyridine derivative with BSA is 
therefore conformation dependent, with a higher efficiency of 
energy transfer from BSA to compound at higher pH (BSA native 
form).    
 
Fig. 10 Excitation spectra of BSA/compound solutions (em=450 
nm) at pH=2; 5; 7 for [BSA]/[compound]=1:1 ([compound]=110-6 
M). 
 
The interaction of compound 1 with the multidrug resistance 
protein MDR1 (1280 amino acids, with 72 tyrosines and 22 
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tryptophans per molecule57) was studied using several 
[MDR1]/[compound] ratios (corresponding to [amino 
acid]/[compound]=46, 92 and 184), keeping [compound] constant. 
Emission of compound 1 is detected for all ratios (decreasing at 
higher concentrations of protein), evidencing FRET from excited 
MDR1 to the thienopyridine derivative, which efficiency decreases 
with increasing protein concentration (Figure 11), as observed for 
BSA. 
Using equations (5)-(8), the values of FRET efficiency, Förster 
radius and donor-acceptor distances were determined (Table 4). The 
donor integrated fluorescence intensity in the presence of acceptor 
(equation 5) was calculated from the emission of the protein in the 
presence of the drug, decomposing the total spectra in two 
components (protein emission and drug emission). 
Comparing the FRET efficiencies of both systems, at 
approximately the same donor/acceptor, [Tyr+Trp]/[compound], 
ratio, it can be observed that RET values are significantly lower for 
the MDR1 protein, showing a stronger interaction of compound 1 
with BSA. Donor-acceptor distances, rAD, are also higher for MDR1 
(Table 4).  
Assuming that compound molecules distribute themselves 
randomly between the proteins, the probability of a subpopulation 
with a given number of compound molecules can be estimated using 
a Poisson distribution. The BSA entries in Table 4 correspond to 
mean occupation values of 1 and 0.5. The probabilities of having 
proteins with 0, 1, 2 and 3 compound molecules are, respectively, 
0.37, 0.37, 0.18, 0.061 (for occupation value 1) and 0.61, 0.30, 
0.076, 0.013 (for occupation value 0.5). The increase of 
subpopulation with no compound molecules results obviously in an 
overall decrease of energy transfer and an apparent increase in 
average donor-acceptor distance. The effect of the decrease in 
subpopulations with two or more compound molecules depends on 
the type of interaction of the compound with protein. If an 
interaction with a specific protein site occurs, no variation of energy 
transfer efficiency is expected. On the contrary, a random 
distribution of compound molecules within the protein would 
predict a decrease in energy transfer efficiency, as this value would 
then be higher in proteins with two or more compound molecules 
(decreased average donor-acceptor distance). The variation with 
more impact is the increase in the subpopulation without compound 
molecules in which energy transfer cannot occur. As a result and 
irrespective of the type of protein-compound interaction, the overall 
efficiency of energy transfer is expected to decrease with the 
increase of protein content and the consequent decrease of average 
compound occupation value. 
The rAD values for BSA at pH=5 and 7 (Table 4) are lower than 
the ones reported for the interaction of other drugs with serum 
albumins, namely the anticancer anastrozole,17 phenylethanoid 
glycosides59 and the flavonol morin.60 This fact points to a high 
affinity of  compound 1 to albumin, but not to MDR1. This high 
affinity indicates that serum albumin (in the native form) is able to 
bind and carry compound 1 in the blood stream. On the other hand, 
the low affinity to human MDR1 gives indication that the compound 
may not be expelled out of the cells by this type of membrane 
proteins (promoters of drug resistance). 
 
 
Fig. 11 Fluorescence spectra of MDR1/compound solutions (exc = 
280 nm) for several [MDR1]/[compound] ratios. Inset: Ratio of 
fluorescence intensities between compound and MDR1, as function 
of MDR1 concentration. 
 
 
Table 4. FRET efficiencies (RET), Förster radius (R0) and 
donor/acceptor distances (rAD) for the interaction of compound 1 
with BSA and MDR1.  
Protein pH 
F of 
proteina 
R0 
(nm) 
[Tyr+Trp]/[1] RET 
rAD 
(nm) 
BSA 
2 0.07 2.3 
11:1 
 0 --- 
22:1 
5 0.17 2.6 
11:1 0.21 3.3 
22:1 0.20 3.3 
7 0.13 2.5 
11:1 0.74 2.1 
22:1 0.51 2.5 
MDR1 7 0.16 2.6 
7:1 0.15 3.5 
14:1 0.06 4.1 
a
 Relative to L-Tryptophan in water, pH=7.2 (F=0.14 at 25 ºC).
58 
 
Drug resistance is one of the major problems in cancer 
chemotherapy. The results presented here are promising for future 
developments using this thienopyridine derivative as an antitumor 
drug. 
Conclusions 
The antitumor methyl 3-amino-6-(benzo[d]thiazol-2-
ylamino)thieno[3,2-b]pyridine-2-carboxylate presents very 
reasonable fluorescence quantum yields and a solvent sensitive 
emission, except in protic solvents. The compound is also 
fluorescent in liposomes, and fluorescence anisotropy 
measurements indicate that it is mainly located in the lipid 
membrane, feeling an increase in fluidity above the melting 
temperature of lipids and by inclusion of cholesterol and 
DMPG in the membranes.  
The lower affinity of this thienopyridine derivative for the 
multidrug resistance protein MDR1, when compared to BSA, is 
promising for the use of this compound as an antitumour drug, 
as MDR1 promotes drug resistance in cells. Furthermore, this 
hydrophobic compound can be transported in nanoliposomes in 
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future drug delivery applications, the Egg-PC:Ch (7:3), Egg-
PC:Ch:DMPG (7:3:1) and DPPC:DMPG (1:2) formulations 
being the best for this compound, exhibiting low size and 
polydispersity. 
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